FACT SHEET FOR HEALTH CARE PROVIDERS
EMERGENCY USE AUTHORIZATION (EUA) OF BAMLANIVIMAB

AUTHORIZED USE

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product bamlanivimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

RECENT MAJOR CHANGES

- Antiviral Resistance (Box and Section 15) - addition of information on susceptibility of SARS-CoV-2 variants to bamlanivimab alone (Table 3)  
  Revised 03/2021
- Other Reporting Requirements (Section 9) - addition of need for healthcare facilities and providers to report therapeutics information and utilization data under EUA  
  Revised 02/2021
- Dose Preparation and Administration Instructions (Section 2.4) - provides updated minimum infusion times based on size of infusion bag used  
  Revised 01/2021
- Warning: Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions (Section 5.1) - addition of new symptoms  
  Revised 01/2021
- Warning: Clinical Worsening After Bamlanivimab Administration (Section 5.2) - new warning added  
  Revised 01/2021

LIMITATIONS OF AUTHORIZED USE

- Bamlanivimab is not authorized for use in patients:
  - who are hospitalized due to COVID-19, OR
  - who require oxygen therapy due to COVID-19, OR
  - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
- Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

Bamlanivimab has been authorized by FDA for the emergency uses described above. Bamlanivimab is not FDA-approved for these uses.

Bamlanivimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
This EUA is for the use of the unapproved product bamlanivimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization [see Limitations of Authorized Use].

High risk is defined as patients who meet at least one of the following criteria:

- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
  - cardiovascular disease, OR
  - hypertension, OR
  - chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 – 17 years of age AND have
  - BMI ≥85th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
  - sickle cell disease, OR
  - congenital or acquired heart disease, OR
  - neurodevelopmental disorders, for example, cerebral palsy, OR
  - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
  - asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control.

Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies. Healthcare providers should review the Antiviral Resistance information in Section 15 of this Fact Sheet for details regarding specific variants and resistance, and refer to the CDC website ([https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html)) as well as information from state and local health authorities regarding reports of viral variants of importance in their region to guide treatment decisions.

The use of alternative authorized monoclonal antibodies that are expected to retain activity against circulating viral variants may reduce the potential risk of treatment failure should a patient be infected with a SARS-CoV-2 viral variant that is resistant to bamlanivimab alone.

**Bamlanivimab must be administered by intravenous (IV) infusion.**

Bamlanivimab may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.
Health care providers must submit a report on all medication errors and **ALL SERIOUS ADVERSE EVENTS** potentially related to bamlanivimab. See Sections 8 and 9 of the Full EUA Prescribing Information for reporting instructions below.

- The authorized dosage for bamlanivimab is a single intravenous (IV) infusion of 700 mg administered as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.
- Bamlanivimab is available as a solution and must be diluted prior to administration.
- Administer bamlanivimab 700 mg as a single IV infusion via pump or gravity (see Table 1).
- Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete.
- Patients treated with bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

The authorized dosage may be updated as additional data from clinical trials becomes available.

For information on clinical trials that are testing the use of bamlanivimab in COVID-19, please see [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**Contraindications**
None.

**Dosing**

**Patient Selection and Treatment Initiation**
This section provides essential information on the unapproved product bamlanivimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization [see Limitations of Authorized Use].

High risk is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
  - cardiovascular disease, OR
  - hypertension, OR
  - chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 – 17 years of age AND have
o BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR
o sickle cell disease, OR
o congenital or acquired heart disease, OR
o neurodevelopmental disorders, for example, cerebral palsy, OR
o a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
o asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

Dosage
The dosage of bamlanivimab in adults and pediatric patients (12 years of age and older weighing at least 40 kg) is:
- bamlanivimab 700 mg.

Administer bamlanivimab as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.

Bamlanivimab must be diluted and administered as a single IV infusion.

Dosage Adjustment in Specific Populations
No dosage adjustment is recommended based on age, sex, race, body weight, renal or mild hepatic impairment, during pregnancy or while lactating, or for disease severity or inflammation [see Full EUA Prescribing Information, Use in Specific Populations (11)].

Preparation and Administration
Preparation
Bamlanivimab solution for infusion should be prepared by a qualified healthcare professional using aseptic technique:
- Gather the materials for preparation:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC, sterile prefilled infusion bag. Choose one of the following sizes:
    - Prefilled 50 mL, 100 mL, 150 mL, or 250 mL infusion bag containing 0.9% Sodium Chloride Injection (see Table 1).
  - One 20 mL vial of bamlanivimab (700 mg/20 mL).
- Remove one bamlanivimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Do not expose to direct heat. Do not shake the vial.
- Inspect bamlanivimab visually for particulate matter and discoloration.
  - Bamlanivimab is a clear to opalescent and colorless to slightly yellow to slightly brown solution.
- Withdraw 20 mL bamlanivimab from one 20 mL vial and inject into a prefilled infusion bag containing 0.9% Sodium Chloride Injection (see Table 1).
- Discard any product remaining in the vial.
- Gently invert IV bag by hand approximately 10 times to mix. Do not shake.
- This product is preservative-free and therefore, the diluted infusion solution should be administered immediately.
  - If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and up to 7 hours at room temperature (20°C to 25°C.
[68°F to 77°F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration.

Administration

Bamlanivimab infusion solution should be administered by a qualified healthcare professional.

- Gather the materials for infusion:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC infusion set
  - Use of an in-line or add-on 0.20/0.22 micron polyethersulfone (PES) filter is strongly recommended.
- Attach the infusion set to the IV bag.
- Prime the infusion set.
- Administer the entire infusion solution in the bag via pump or gravity according to the size of infusion bag used (see Table 1). Due to potential overfill of prefilled saline bags, the entire infusion solution in the bag should be administered to avoid underdosage.
- The prepared infusion solution should not be administered simultaneously with any other medication. The compatibility of bamlanivimab with IV solutions and medications other than 0.9% Sodium Chloride Injection is not known.
- Once infusion is complete, flush the tubing with 0.9% Sodium Chloride to ensure delivery of the required dose.
- Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete.
- If the infusion must be discontinued due to an infusion reaction, discard any unused product.
- The use of closed system transfer devices (CSTDs), elastomeric pumps, and pneumatic transport with bamlanivimab has not been studied.

Table 1: Recommended Dilution and Administration Instructions for Bamlanivimab

| Drug: Add 20 mL of bamlanivimab (1 vial) to a prefilled infusion bag and administer as instructed below |
|---|---|---|
| Size of prefilled 0.9% Sodium Chloride infusion bag | Maximum Infusion Rate | Minimum Infusion Time |
| 50 mL | 270 mL/hr | 16 minutes |
| 100 mL | 270 mL/hr | 27 minutes |
| 150 mL | 270 mL/hr | 38 minutes |
| 250 mL | 270 mL/hr | 60 minutes |

* 700 mg of bamlanivimab (20 mL) is added to an infusion bag and administered as a single intravenous infusion.

Storage

Refrigerate unopened vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze, shake, or expose to direct light.
Warnings
There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.

Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy.

Infusion-related reactions have been observed with administration of bamlanivimab. These reactions may be severe or life threatening.

Signs and symptoms of infusion-related reactions may include:
- fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchosospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness, and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.

Clinical Worsening After Bamlanivimab Administration
Clinical worsening after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to bamlanivimab use or were due to progression of COVID-19.

Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19
Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, bamlanivimab is not authorized for use in patients [see Limitations of Authorized Use]:
- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
- who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Side Effects
Adverse events have been reported with bamlanivimab [see Full EUA Prescribing Information, Clinical Trials Experience (6.1)].

Additional adverse events associated with the drug may become apparent with more widespread use.
INSTRUCTIONS FOR HEALTHCARE PROVIDERS

As the healthcare provider, you must communicate to your patient or parent/caregiver, as age appropriate, information consistent with the “Fact Sheet for Patients, Parents and Caregivers” (and provide a copy of the Fact Sheet) prior to the patient receiving bamlanivimab, including:

- FDA has authorized the emergency use of bamlanivimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization [see Limitations of Authorized Use].
- The patient or parent/caregiver has the option to accept or refuse bamlanivimab.
- The significant known and potential risks and benefits of bamlanivimab, and the extent to which such potential risks and benefits are unknown.
- Information on available alternative treatments and the risks and benefits of those alternatives, including clinical trials.
- Patients treated with bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

For information on clinical trials that are testing the use of bamlanivimab for COVID-19, please see www.clinicaltrials.gov.

MANDATORY REQUIREMENTS FOR BAMLANIVIMAB ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION:

In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of bamlanivimab, the following items are required. Use of bamlanivimab under this EUA is limited to the following (all requirements must be met):

1. Treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization [see Limitations of Authorized Use].
2. As the healthcare provider, communicate to your patient or parent/caregiver, as age appropriate, information consistent with the “Fact Sheet for Patients, Parents and Caregivers” prior to the patient receiving bamlanivimab. Healthcare providers (to the extent practicable given the circumstances of the emergency) must document in the patient’s medical record that the patient/caregiver has been:
   a. Given the “Fact Sheet for Patients, Parents and Caregivers”,
   b. Informed of alternatives to receiving authorized bamlanivimab, and
   c. Informed that bamlanivimab is an unapproved drug that is authorized for use under this Emergency Use Authorization.
3. Patients with known hypersensitivity to any ingredient of bamlanivimab must not receive bamlanivimab.
4. The prescribing health care provider and/or the provider’s designee are/is responsible for mandatory reporting of all medication errors and serious adverse events* potentially related to bamlanivimab treatment within 7 calendar days from the onset of the event. The reports should include unique identifiers and the words “Bamlanivimab treatment under Emergency Use Authorization (EUA)” in the description section of the report.
Submit adverse event reports to FDA MedWatch using one of the following methods:

- Complete and submit the report online: www.fda.gov/medwatch/report.htm, or
- By using a postage-paid Form FDA 3500 (available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf) and returning by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787), or by fax (1-800-FDA-0178), or
- Call 1-800-FDA-1088 to request a reporting form
- Submitted reports should include in the field name, “Describe Event, Problem, or Product Use/Medication Error” the statement “Bamlanivimab treatment under Emergency Use Authorization (EUA)”

*Serious Adverse Events are defined as:

- death;
- a life-threatening adverse event;
- inpatient hospitalization or prolongation of existing hospitalization;
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- a congenital anomaly/birth defect;
- a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly.

5. The prescribing health care provider and/or the provider’s designee are/is to provide mandatory responses to requests from FDA for information about adverse events and medication errors following receipt of bamlanivimab.

6. OTHER REPORTING REQUIREMENTS

- Healthcare facilities and providers must report therapeutics information and utilization data through HHS Protect, Teletracking or National Healthcare Safety Network (NHSN) as directed by the U.S. Department of Health and Human Services.

- In addition, please provide a copy of all FDA MedWatch forms to:
  Eli Lilly and Company, Global Patient Safety
  Fax: 1-317-277-0853
  E-mail: phallindata_gsmtindy@lilly.com
  Or call Eli Lilly and Company at 1-855-LillyC19 (1-855-545-5921) to report adverse events.

APPROVED AVAILABLE ALTERNATIVES

There is no adequate, approved and available alternative to bamlanivimab for patients who have mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization. Additional information on COVID-19 treatments can be found at https://www.cdc.gov/coronavirus/2019-ncov/index.html. The health care provider should visit https://clinicaltrials.gov/ to determine whether the patient may be eligible for enrollment in a clinical trial.
AUTHORITY FOR ISSUANCE OF THE EUA

The Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency that justifies the emergency use of drugs and biological products during the COVID-19 pandemic. FDA has issued this EUA, requested by Eli Lilly and Company for the unapproved product bamlanivimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.¹ As a health care provider, you must comply with the mandatory requirements of the EUA (see above).

Although limited scientific information is available, based on the totality of the scientific evidence available to date, it is reasonable to believe that bamlanivimab may be effective for the treatment of mild to moderate COVID-19 in certain high-risk patients as specified in this Fact Sheet. You may be contacted and asked to provide information to help with the assessment of the use of the product during this emergency.

This EUA for bamlanivimab will end when the Secretary determines that the circumstances justifying the EUA no longer exist or when there is a change in the approval status of the product such that an EUA is no longer needed.

CONTACT INFORMATION
For additional information visit www.bamlanivimab.com

If you have questions, please contact 1-855-LillyC19 (1-855-545-5921)

¹ The health care provider should visit clinicaltrials.gov to determine whether there is an active clinical trial for the product in this disease/condition and whether enrollment of the patient(s) in a clinical trial is more appropriate than product use under this EUA.
FULL EUA PRESCRIBING INFORMATION

FULL EUA PRESCRIBING INFORMATION: CONTENTS*

1 AUTHORIZED USE

2 DOSAGE AND ADMINISTRATION
   2.1 Patient Selection
   2.2 Dosage
   2.3 Dosage Adjustment in Specific Populations
   2.4 Dose Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
   5.1 Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions
   5.2 Clinical Worsening After Bamlanivimab Administration
   5.3 Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19

6 OVERALL SAFETY SUMMARY
   6.1 Clinical Trials Experience

7 PATIENT MONITORING RECOMMENDATIONS

8 ADVERSE REACTIONS AND MEDICATION ERRORS REPORTING REQUIREMENTS AND INSTRUCTIONS

9 OTHER REPORTING REQUIREMENTS

10 DRUG INTERACTIONS

11 USE IN SPECIFIC POPULATIONS
   11.1 Pregnancy
   11.2 Lactation
   11.3 Pediatric Use
   11.4 Geriatric Use
   11.5 Renal Impairment
   11.6 Hepatic Impairment
   11.7 Other Specific Populations

12 OVERDOSAGE

13 DESCRIPTION

14 CLINICAL PHARMACOLOGY
   14.1 Mechanism of Action
   14.2 Pharmacodynamics
   14.3 Pharmacokinetics

15 MICROBIOLOGY/RESISTANCE INFORMATION

16 NONCLINICAL TOXICOLOGY

17 ANIMAL PHARMACOLOGIC AND EFFICACY DATA

18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA
   18.1 Mild to Moderate COVID-19 (BLAZE-1)

19 HOW SUPPLIED/STORAGE AND HANDLING

20 PATIENT COUNSELING INFORMATION

21 CONTACT INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

1 AUTHORIZED USE

Bamlanivimab is authorized for use under an EUA for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

LIMITATIONS OF AUTHORIZED USE

- Bamlanivimab is not authorized for use in patients:
  - who are hospitalized due to COVID-19, OR
  - who require oxygen therapy due to COVID-19, OR
  - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

- Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation [see Warnings and Precautions (5.3)].
2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection
Bamlanivimab should be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset in adults and pediatric patients (12 years of age and older weighing at least 40 kg), who are at high risk for progressing to severe COVID-19 and/or hospitalization.

High risk is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
  - cardiovascular disease, OR
  - hypertension, OR
  - chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 – 17 years of age AND have
  - BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR
  - sickle cell disease, OR
  - congenital or acquired heart disease, OR
  - neurodevelopmental disorders, for example, cerebral palsy, OR
  - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
  - asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

2.2 Dosage
The dosage of bamlanivimab in adults and pediatric patients (12 years of age and older weighing at least 40 kg) is:
- bamlanivimab 700 mg.

Administer bamlanivimab as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.

Bamlanivimab must be diluted and administered as a single IV infusion.

2.3 Dosage Adjustment in Specific Populations

Pregnancy or Lactation
No dosage adjustment is recommended in pregnant or lactating women [see Use in Specific Populations (11.1, 11.2)].
Pediatric Use
No dosage adjustment is recommended in pediatric patients who weigh at least 40 kg and are 12 years of age and older. Bamlanivimab is not authorized for patients weighing less than 40 kg or those less than 12 years of age [see Use in Specific Populations (11.3)].

Geriatric Use
No dosage adjustment is recommended in geriatric patients [see Use in Specific Populations (11.4)].

Renal Impairment
No dosage adjustment is recommended in patients with renal impairment [see Use in Specific Populations (11.5)].

Hepatic Impairment
No dosage adjustment is recommended in patients with mild hepatic impairment. Bamlanivimab has not been studied in patients with moderate or severe hepatic impairment [see Use in Specific Populations (11.6)].

2.4 Dose Preparation and Administration

Preparation
Bamlanivimab solution for infusion should be prepared by a qualified healthcare professional using aseptic technique:

- Gather the materials for preparation:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC, sterile prefilled infusion bag. Choose one of the following sizes:
    - Prefilled 50 mL, 100 mL, 150 mL, or 250 mL infusion bag containing 0.9% Sodium Chloride Injection (see Table 1).
  - One 20 mL vial of bamlanivimab (700 mg/20 mL).
- Remove one bamlanivimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Do not expose to direct heat. Do not shake the vial.
- Inspect bamlanivimab visually for particulate matter and discoloration.
  - Bamlanivimab is a clear to opalescent and colorless to slightly yellow to slightly brown solution.
- Withdraw 20 mL bamlanivimab from one 20 mL vial and inject into a prefilled infusion bag containing 0.9% Sodium Chloride Injection (see Table 1).
- Discard any product remaining in the vial.
- Gently invert IV bag by hand approximately 10 times to mix. Do not shake.
- This product is preservative-free and therefore, the diluted infusion solution should be administered immediately.
  - If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and up to 7 hours at room temperature (20°C to 25°C [68°F to 77°F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration.
Administration
Bamlanivimab infusion solution should be administered by a qualified healthcare professional.

- Gather the materials for infusion:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC infusion set
  - Use of an in-line or add-on 0.20/0.22 micron polyethersulfone (PES) filter is strongly recommended.

- Attach the infusion set to the IV bag.

- Prime the infusion set.

- Administer the entire infusion solution in the bag via pump or gravity according to the size of infusion bag used (see Table 1). Due to potential overfill of prefilled saline bags, the entire infusion solution in the bag should be administered to avoid underdosage.

- The prepared infusion solution should not be administered simultaneously with any other medication. The compatibility of bamlanivimab with IV solutions and medications other than 0.9% Sodium Chloride Injection is not known.

- Once infusion is complete, flush the tubing with 0.9% Sodium Chloride to ensure delivery of the required dose.

- Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete.

- If the infusion must be discontinued due to an infusion reaction, discard any unused product.

- The use of closed system transfer devices (CSTDs), elastomeric pumps, and pneumatic transport with bamlanivimab has not been studied.

Table 1: Recommended Dilution and Administration Instructions for Bamlanivimab

<table>
<thead>
<tr>
<th>Size of prefilled 0.9% Sodium Chloride infusion bag</th>
<th>Maximum Infusion Rate</th>
<th>Minimum Infusion Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mL</td>
<td>270 mL/hr</td>
<td>16 minutes</td>
</tr>
<tr>
<td>100 mL</td>
<td>270 mL/hr</td>
<td>27 minutes</td>
</tr>
<tr>
<td>150 mL</td>
<td>270 mL/hr</td>
<td>38 minutes</td>
</tr>
<tr>
<td>250 mL</td>
<td>270 mL/hr</td>
<td>60 minutes</td>
</tr>
</tbody>
</table>

* 700 mg of bamlanivimab (20 mL) is added to an infusion bag and administered as a single intravenous infusion.

Storage
This product is preservative-free and therefore, the diluted infusion solution should be administered immediately. If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and up to 7 hours at room temperature (20°C to 25°C [68°F to 77°F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration.
3 DOSAGE FORMS AND STRENGTHS

Bamlanivimab is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow to slightly brown solution available as:

- Injection: 700 mg/20 mL (35 mg/mL) in a single-dose vial.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.

5.1 Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.

Infusion-related reactions have been observed with administration of bamlanivimab. These reactions may be severe or life threatening.

Signs and symptoms of infusion related reactions may include:

- fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.

5.2 Clinical Worsening After Bamlanivimab Administration

Clinical worsening of COVID-19 after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to bamlanivimab use or were due to progression of COVID-19.

5.3 Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, bamlanivimab is not authorized for use in patients [see Limitations of Authorized Use]:

- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

6 OVERALL SAFETY SUMMARY

Over 1350 subjects have been exposed to bamlanivimab in clinical trials in both hospitalized and non-hospitalized patients.

6.1 Clinical Trials Experience

The safety of bamlanivimab is based on interim data from one Phase 2 trial of 465 ambulatory (non-hospitalized) subjects with COVID-19.

BLAZE-1 is a randomized, double-blind, placebo-controlled clinical trial in ambulatory adults with mild to moderate COVID-19 symptoms who had sample collection for the first positive SARS-CoV-2 viral infection determination within 3 days prior to the start of the infusion. Subjects were treated with a single infusion of bamlanivimab at doses of 700 mg (N=101), 2,800 mg (N=107), or 7,000 mg (N=101) or placebo (N=156).

Based on data from 309 bamlanivimab-treated subjects followed for at least 28 days after treatment, adverse events occurred in 23% bamlanivimab-treated subjects and 26% of placebo-treated subjects. Serious adverse events occurred in 1 placebo-treated subject (1%) and in no bamlanivimab-treated subjects.

The most commonly reported adverse event was nausea. Table 2 shows adverse events reported in at least 1% of patients in any treatment group. Bamlanivimab is not authorized at doses of 2,800 mg or 7,000 mg.

### Table 2: Treatment-emergent Adverse Events Reported in at Least 1% of All Subjects in BLAZE-1

<table>
<thead>
<tr>
<th>Preferred term</th>
<th>Placebo N=156 %</th>
<th>700 mg N=101 %</th>
<th>2,800 mg N=107 %</th>
<th>7,000 mg N=101 %</th>
<th>Total N=309 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>4%</td>
<td>3%</td>
<td>4%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5%</td>
<td>1%</td>
<td>2%</td>
<td>7%</td>
<td>3%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Headache</td>
<td>2%</td>
<td>3%</td>
<td>2%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1%</td>
<td>2%</td>
<td>3%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
<td>1%</td>
<td>3%</td>
<td>1%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Hypersensitivity Including Anaphylaxis and Infusion-related Reactions:

Across ongoing, blinded clinical trials, a case of anaphylaxis and other cases of serious infusion-related reactions were reported with infusion of bamlanivimab. The infusions were stopped. All reactions required treatment, one required epinephrine. All events resolved.

Immediate non-serious hypersensitivity events were noted for 2% of bamlanivimab-treated subjects and 1% of placebo-treated subjects in BLAZE-1. Reported events of
pruritus, flushing and hypersensitivity were mild with one case of face swelling which was moderate. All events resolved [see Warnings and Precautions (5.1)].

7 PATIENT MONITORING RECOMMENDATIONS
 Clinically monitor patients during infusion and observe patients for at least 1 hour after infusion is complete [see Warnings and Precautions (5.1) and Clinical Trials Experience (6.1)].

8 ADVERSE REACTIONS AND MEDICATION ERRORS REPORTING REQUIREMENTS AND INSTRUCTIONS
 Clinical trials evaluating the safety of bamlanivimab are ongoing [see Overall Safety Summary (6)].

Completion of FDA MedWatch Form to report all medication errors and serious adverse events is mandatory. The prescribing healthcare provider and/or the provider’s designee are/is responsible for the mandatory reporting of all medication errors and the following serious adverse events occurring during bamlanivimab use and considered to be potentially related to bamlanivimab. These adverse events must be reported within 7 calendar days from the onset of the event:
- death;
- a life-threatening adverse event;
- inpatient hospitalization or prolongation of existing hospitalization;
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- a congenital anomaly/birth defect;
- a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly.

If a serious and unexpected adverse event occurs and appears to be associated with the use of bamlanivimab, the prescribing healthcare provider and/or the provider’s designee should complete and submit a MedWatch form to FDA using one of the following methods:
- Complete and submit the report online: www.fda.gov/medwatch/report.htm, or
- Use a postage-paid Form FDA 3500 (available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf) and returning by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787), or by fax (1-800-FDA-0178), or
- Call 1-800-FDA-1088 to request a reporting form

IMPORTANT: When reporting adverse events or medication errors to MedWatch, please complete the entire form with detailed information. It is important that the information reported to FDA be as detailed and complete as possible. Information to include:
- Patient demographics (e.g., patient initials, date of birth)
- Pertinent medical history
- Pertinent details regarding adverse events and course of illness
- Concomitant medications
- Timing of adverse event(s) in relationship to administration of bamlanivimab
• Pertinent laboratory and virology information
• Outcome of the event and any additional follow-up information if it is available at the time of the MedWatch report. Subsequent reporting of follow-up information should be completed if additional details become available.

The following steps are highlighted to provide the necessary information for safety tracking:
• In section A, box 1, provide the patient’s initials in the Patient Identifier
• In section A, box 2, provide the patient’s date of birth
• In section B, box 5, description of the event:
  o Write “Bamlanivimab treatment under Emergency Use Authorization (EUA)” as the first line
  o Provide a detailed report of medication error and/or adverse event. It is important to provide detailed information regarding the patient and adverse event/medication error for ongoing safety evaluation of this unapproved drug. Please see information to include listed above.
• In section G, box 1, name and address:
  o Provide the name and contact information of the prescribing healthcare provider or institutional designee who is responsible for the report.
  o Provide the address of the treating institution (NOT the healthcare provider’s office address).

9 OTHER REPORTING REQUIREMENTS
• Healthcare facilities and providers must report therapeutics information and utilization data through HHS Protect, Teletracking or National Healthcare Safety Network (NHSN) as directed by the U.S. Department of Health and Human Services.

• In addition, please provide a copy of all FDA MedWatch forms to:
  Eli Lilly and Company, Global Patient Safety
  Fax: 1-317-277-9853
  E-mail: mailindata_gsmindy@lilly.com
  Or call Eli Lilly and Company at 1-855-LillyC19 (1-855-545-5921) to report adverse events.

10 DRUG INTERACTIONS
Bamlanivimab is not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.

11 USE IN SPECIFIC POPULATIONS
11.1 Pregnancy

Risk Summary
There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Bamlanivimab should only be used
during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Nonclinical reproductive toxicity studies have not been performed with bamlanivimab. In a tissue cross reactivity study with bamlanivimab using human fetal tissues, no binding of clinical concern was detected. Human immunoglobulin G1 (IgG1) antibodies are known to cross the placental barrier; therefore, bamlanivimab has the potential to be transferred from the mother to the developing fetus. It is unknown whether the potential transfer of bamlanivimab provides any treatment benefit or risk to the developing fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

11.2 Lactation
Risk Summary
There are no available data on the presence of bamlanivimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for bamlanivimab and any potential adverse effects on the breastfed child from bamlanivimab or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

11.3 Pediatric Use
The safety and effectiveness of bamlanivimab have not been assessed in pediatric patients. The recommended dosing regimen is expected to result in comparable serum exposures of bamlanivimab in patients 12 years of age and older and weighing at least 40 kg as observed in adults, based on a pharmacokinetic (PK) modeling approach which accounted for effect of body weight changes associated with age on clearance and volume of distribution.

11.4 Geriatric Use
Of the 309 patients receiving bamlanivimab in BLAZE-1, 11% were 65 years of age and older and 3% were 75 years of age and older. Based on population PK analyses, there is no difference in PK in geriatric patients compared to younger patients.

11.5 Renal Impairment
Bamlanivimab is not eliminated intact in the urine, thus renal impairment is not expected to affect the exposure of bamlanivimab.

11.6 Hepatic Impairment
Based on population PK analysis, there is no significant difference in PK of bamlanivimab in patients with mild hepatic impairment compared to patients with normal hepatic function. Bamlanivimab has not been studied in patients with moderate or severe hepatic impairment.
11.7 Other Specific Populations
Based on population PK analysis, the PK of bamlanivimab was not affected by sex, race, or disease severity. Body weight had no clinically relevant effect on the PK of bamlanivimab in adults with COVID-19 over the body weight range of 41 kg to 173 kg.

12 OVERDOSAGE
Doses up to 7,000 mg (10 times the recommended dose) have been administered in clinical trials without dose-limiting toxicity. Treatment of overdose with bamlanivimab should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with bamlanivimab.

13 DESCRIPTION
Bamlanivimab is a human immunoglobulin G-1 (IgG1 variant) monoclonal antibody consisting of 2 identical light chain polypeptides composed of 214 amino acids each and 2 identical heavy chain polypeptides composed of 455 amino acids produced by a Chinese Hamster Ovary (CHO) cell line and molecular weight of <46 kDa. Bamlanivimab injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow to slightly brown solution in a single-dose vial for intravenous infusion after dilution.

Each mL contains 35 mg of bamlanivimab, and L-histidine (0.4 mg), L-histidine hydrochloride monohydrate (0.6 mg), sodium chloride (2.9 mg), sucrose (60 mg), polysorbate 80 (0.5 mg), and Water for Injection. The bamlanivimab solution has a pH range of 5.5-6.5.

14 CLINICAL PHARMACOLOGY
14.1 Mechanism of Action
Bamlanivimab is a recombinant, neutralizing human IgG1κ monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region. Bamlanivimab binds to spike protein with a dissociation constant $K_D = 0.071$ nM and blocks spike protein attachment to the human ACE2 receptor with an IC$_{50}$ value of 0.025 µg/mL.

14.2 Pharmacodynamics
A Phase 2 trial evaluated bamlanivimab over a dose range of 1 to 10 times the recommended dose (700 to 7000 mg) of bamlanivimab in patients with mild to moderate COVID-19. A flat exposure-response relationship for efficacy was identified for bamlanivimab within this dose range, based on viral load and clinical outcomes.

14.3 Pharmacokinetics
The pharmacokinetic profile of bamlanivimab is linear and dose proportional between 700 mg and 7000 mg following a single IV administration. There were no differences in PK of bamlanivimab between severe/moderate participants who were hospitalized and mild/moderate ambulatory participants.
Absorption
The mean maximum concentration (Cmax) of 700 mg bamlanivimab was 196 µg/mL (90% CI: 102 to 378 µg/mL) following approximately 1 hour 700 mg IV infusion.

Distribution
Bamlanivimab mean volume of distribution (V) was 2.87 L and 2.71 L for the central and peripheral compartments, respectively. The between subject variability was 23.2% CV.

Metabolism
Bamlanivimab is expected to be degraded into small peptides and component amino acids via catabolic pathways in the same manner as endogenous IgG antibodies.

Elimination
Bamlanivimab clearance (CL) was 0.27 L/hr (between subject variability 22.3% CV) and the mean apparent terminal elimination half-life was 17.6 days (between subject variability 15.8% CV). Following a single 700 mg IV dose, bamlanivimab was quantifiable for at least 29 days. The mean concentration was 22 µg/mL (90% CI: 10.7 to 41.6 µg/mL) on Day 29.

Special Populations:
The PK profile of bamlanivimab was not affected by age, sex, race, or disease severity based on a population PK analysis. Body weight had no clinically relevant effect on the PK of bamlanivimab in adults with COVID-19 over the body weight range of 41 kg to 173 kg [see Use in Specific Populations (11.4, 11.7)].

Pediatric population
The PK of bamlanivimab in pediatric patients have not been evaluated.

Using modeling and simulation, the recommended dosing regimen is expected to result in comparable plasma exposures of bamlanivimab in pediatric patients ages 12 years of age or older who weigh at least 40 kg as observed in adult patients [see Use in Specific Populations (11.3)].

Patients with renal impairment
Bamlanivimab is not eliminated intact in the urine, thus renal impairment is not expected to affect the exposure of bamlanivimab [see Use in Specific Populations (11.5)].

Patients with hepatic impairment
Based on population PK analysis, there is no significant difference in PK of bamlanivimab in patients with mild hepatic impairment compared to patients with normal hepatic function. Bamlanivimab has not been studied in patients with moderate or severe hepatic impairment [see Use in Specific Populations (11.6)].

Drug interactions:
Bamlanivimab is not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.
15 MICROBIOLOGY/RESISTANCE INFORMATION

Antiviral Activity
The cell culture neutralization activity of bamlanivimab against SARS-CoV-2 was measured in a dose-response model quantifying plaque reduction using cultured Vero E6 cells. Bamlanivimab neutralized the USA/WA/1/2020 isolate of SARS-CoV-2 with an estimated EC\textsubscript{50} value = 0.14 nM (0.02 µg/mL).

Bamlanivimab demonstrated antibody-dependent cell-mediated cytotoxicity on reporter Jurkat cells expressing FcγRIIIa following engagement with target cells expressing spike protein. Bamlanivimab did not elicit complement-dependent cytotoxicity activity in cell-based assays.

Antibody Dependent Enhancement (ADE) of Infection
The risk that bamlanivimab could mediate viral uptake and replication by immune cells was studied in THP-1 and Raji cell lines and primary human macrophages. This experiment did not demonstrate productive viral infection in immune cells exposed to SARS-CoV-2 at concentrations of bamlanivimab down to 100-fold below the EC\textsubscript{50} value.

Antiviral Resistance
There is a potential risk of treatment failure due to the development of viral SARS-CoV-2 variants that are resistant to bamlanivimab. Prescribing healthcare providers should consider the prevalence of bamlanivimab resistance variants in their area, where data are available, when considering treatment options.

Non-clinical studies using serial passage of SARS-CoV-2 and directed evolution of the spike protein identified amino acid substitutions E484D/K/Q, F490S, Q493R and S494P, in the spike protein receptor binding domain. These substitutions conferred reduced susceptibility to bamlanivimab as determined in neutralization assays using SARS-CoV-2 (F490S and S494P: >485-fold and >71-fold reduction, respectively), vesicular stomatitis virus-based pseudovirus expressing spike protein with variant substitutions (all variants >100-fold reduction), and spike protein binding assessment if pseudovirus assessment was unsuccessful (E484D).

Evaluation of susceptibility of variants identified through global surveillance and in subjects treated with bamlanivimab is ongoing. Pseudovirus harboring the E484K substitution had reduced susceptibility to bamlanivimab; this substitution is found in several lineages, including B.1.351 (South Africa origin), P.1 (Brazil origin) and B.1.526 (New York origin). In addition, pseudoviruses with the spike protein and concurrent spike substitutions present in the South African B.1.351 origin variant lineage (K417N + E484K + N501Y), and the Brazil origin P.1 variant lineage (K417T + E484K + N501Y) exhibited reduced susceptibility to bamlanivimab. Pseudovirus harboring the L452R and the spike protein from the California origin variant lineage B.1.427/B.1.429 exhibited reduced susceptibility to bamlanivimab. Bamlanivimab retained activity against pseudovirus expressing del69-70 + N501Y spike substitutions found in the UK origin B.1.1.7 variant lineage (Table 3).
Table 3: Pseudovirus Neutralization Data for SARS-CoV-2 Variant Substitutions with Bamlanivimab Alone

<table>
<thead>
<tr>
<th>Lineage with Spike Protein Substitution</th>
<th>Key Substitutions Testeda</th>
<th>Fold Reduction in Susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7 (UK origin)</td>
<td>N501Y</td>
<td>no changeb</td>
</tr>
<tr>
<td>B.1.351 (South Africa origin)</td>
<td>E484K</td>
<td>&gt;2,360c</td>
</tr>
<tr>
<td>P.1 (Brazil origin)</td>
<td>E484K</td>
<td>&gt;2,360c</td>
</tr>
<tr>
<td>B.1.427/B.1.429 (California origin)</td>
<td>L452R</td>
<td>&gt;1,020c</td>
</tr>
<tr>
<td>B.1.526 (New York origin)d</td>
<td>E484K</td>
<td>&gt;2,360c</td>
</tr>
</tbody>
</table>

a For variants with more than one substitution of concern, only the one with the greatest impact on activity is listed.
b No change: <5-fold reduction in susceptibility.
c No activity was observed at the highest concentration tested. Bamlanivimab alone is unlikely to be active against variants from this lineage.
d Not all isolates of the New York lineage harbor the E484K substitution (as of February 2021).

It is not known how pseudovirus data correlate with clinical outcomes; however, reduction in susceptibility of >1,000-fold indicates that there will likely be no activity of bamlanivimab alone against these variants.

Genotypic and phenotypic testing are ongoing to monitor for potential bamlanivimab-resistance-associated spike variations in clinical trials. Known bamlanivimab-resistant variants at baseline were observed at a frequency of 0.27% (1/375) in the clinical trial BLAZE-1. In the same trial, treatment-emergent variants were detected at spike protein amino acid positions E484, F490 and S494, and included E484A/D/G/K/Q/V, F490L/S/V and S494L/P; only E484K/Q, F490S and S494P have been assessed phenotypically to date. Considering all variants detected at positions E484, F490 and S494, 9.2% (9/98) and 6.1% (6/98) of participants in the 700 mg bamlanivimab arm harbored such a variant post-baseline at ≥15% and ≥50% allele fractions, respectively, compared with 8.2% (8/97) and 4.1% (4/97), respectively, of participants in the placebo arm. Most of these variants were first detected on Day 7 following treatment initiation and many were detected only at a single time point (700 mg arm: 5/9 and 2/6 at ≥15% and ≥50% allele fractions, respectively, placebo arm: 8/8 and 4/4, respectively). For the 700 mg bamlanivimab arm, these variants were detected more frequently in high-risk participants (14.0% [6/43] and 9.3% [4/43] at ≥15% and ≥50% allele fractions, respectively, vs 2.4% [1/41] and 0% [0/41], respectively, in the placebo arm). The clinical relevance of these findings is not known.

It is possible that bamlanivimab resistance-associated variants could have cross-resistance to other mAbs targeting the receptor binding domain of SARS-CoV-2. The clinical impact is not known.

Immune Response Attenuation
There is a theoretical risk that antibody administration may attenuate the endogenous immune response to SARS-CoV-2 and make patients more susceptible to re-infection.

16 NONCLINICAL TOXICOLOGY
Carcinogenesis, mutagenesis, and reproductive toxicology studies with bamlanivimab have not been conducted.
In toxicology studies in rats, bamlanivimab had no adverse effects when administered intravenously. Non-adverse increases in neutrophils were observed.

In tissue cross reactivity studies using human adult and fetal tissues, no binding of clinical concern was detected.

17 ANIMAL PHARMACOLOGIC AND EFFICACY DATA

In Vivo Efficacy Pharmacology
Prophylactic administration of bamlanivimab to female Rhesus macaques (n=3 or 4 per group) resulted in 1 to 4 log\(_{10}\) decreases in viral load (genomic RNA) and viral replication (sub-genomic RNA) in bronchoalveolar lavage samples relative to control animals, but less of an impact on viral RNA in throat and nasal swabs following SARS-CoV-2 inoculation. The applicability of these findings to a prophylaxis or treatment setting is not known.

18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA

18.1 Mild to Moderate COVID-19 (BLAZE-1)

The data supporting this EUA are based on an interim analysis from BLAZE-1 that occurred after all enrolled subjects completed at least Day 29 of the trial. BLAZE-1 is a randomized, double-blind, placebo-controlled clinical trial studying bamlanivimab for the treatment of subjects with mild to moderate COVID-19 (subjects with COVID-19 symptoms who are not hospitalized). BLAZE-1 enrolled adult patients who were not hospitalized and had at least 1 or more COVID-19 symptoms that were at least mild in severity. Treatment was initiated within 5 days of obtaining the clinical sample for the first positive SARS-CoV-2 viral infection determination. Subjects were treated with a single infusion of bamlanivimab (at doses of 700 mg [N=101], 2,800 mg [N=107], or 7,000 mg [N=101]) or placebo (N=156).

At baseline, median age was 45 years (with 12% of subjects aged 65 or older); 55% of subjects were female, 88% were White, 44% were Hispanic or Latino, and 6% were Black; 44% of subjects were considered high risk (as defined in Section 2). Subjects had mild (76%) to moderate COVID-19 (24%); the mean duration of symptoms was 5 days; mean viral load by cycle threshold (CT) was 24 at baseline. The baseline demographics and disease characteristics were well balanced across bamlanivimab and placebo treatment groups.

The pre-specified primary endpoint in this Phase 2 trial was change in viral load from baseline to Day 11 for bamlanivimab versus placebo. Most subjects, including those receiving placebo, effectively cleared virus by Day 11 (Figure 1).
While viral load was used to define the primary endpoint in this Phase 2 trial, the most important evidence that bamlanivimab may be effective came from the predefined secondary endpoint of COVID-19-related hospitalizations or emergency room visits within 28 days after treatment. A lower proportion of bamlanivimab-treated subjects progressed to COVID-19-related hospitalization or emergency room visits compared to placebo-treated subjects (Table 4). Results for this endpoint were suggestive of a relatively flat dose-response relationship.

Table 4: Proportion of Subjects with Events of Hospitalization or Emergency Room Visits within 28 Days After Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N(^a)</th>
<th>Events</th>
<th>Proportion of Subjects %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>156</td>
<td>9</td>
<td>6%</td>
</tr>
<tr>
<td>bamlanivimab 700 mg</td>
<td>101</td>
<td>1</td>
<td>1%</td>
</tr>
<tr>
<td>bamlanivimab 2800 mg</td>
<td>107</td>
<td>2</td>
<td>2%</td>
</tr>
<tr>
<td>bamlanivimab 7000 mg</td>
<td>101</td>
<td>2</td>
<td>2%</td>
</tr>
<tr>
<td>All bamlanivimab doses</td>
<td>309</td>
<td>5</td>
<td>2%</td>
</tr>
</tbody>
</table>

\(^a\) N = number of treated patients in analysis.

The absolute risk reduction for bamlanivimab compared to placebo is greater in subjects at higher risk of hospitalization according to the high risk criteria (Table 5).
Table 5: Proportion of Subjects with Events of Hospitalization or Emergency Room Visits for Subjects at Higher Risk of Hospitalization

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Events</th>
<th>Proportion of Subjects %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>69</td>
<td>7</td>
<td>10%</td>
</tr>
<tr>
<td>bamlanivimab 700 mg</td>
<td>46</td>
<td>1</td>
<td>2%</td>
</tr>
<tr>
<td>bamlanivimab 2800 mg</td>
<td>46</td>
<td>1</td>
<td>2%</td>
</tr>
<tr>
<td>bamlanivimab 7000 mg</td>
<td>44</td>
<td>2</td>
<td>5%</td>
</tr>
<tr>
<td>All bamlanivimab doses</td>
<td>136</td>
<td>4</td>
<td>3%</td>
</tr>
</tbody>
</table>

<sup>a</sup> N = number of treated patients in analysis.

The median time to symptom improvement as recorded in a trial specific daily symptom diary was 6 days for bamlanivimab-treated subjects, as compared with 8 days for placebo-treated subjects. Symptoms assessed were cough, shortness of breath, feeling feverish, fatigue, body aches and pains, sore throat, chills, and headache. Symptom improvement was defined as symptoms scored as moderate or severe at baseline being scored as mild or absent, and symptoms scored as mild or absent at baseline being scored as absent.

19 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

Bamlanivimab injection is a sterile, preservative-free clear to opalescent and colorless to slightly yellow to slightly brown solution supplied in a single-dose vial.

Bamlanivimab is supplied as:

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Concentration</th>
<th>Package Size</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bamlanivimab</td>
<td>700 mg/20 mL (35 mg/mL)</td>
<td>one vial per carton</td>
<td>0002-7910-01</td>
</tr>
</tbody>
</table>

Storage and Handling

Bamlanivimab is preservative-free. Discard unused portion.

Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.

DO NOT FREEZE, SHAKE, OR EXPOSE TO DIRECT LIGHT.

Solution in vial requires dilution prior to administration. The prepared infusion solution is intended to be used immediately. If immediate administration is not possible, store diluted bamlanivimab infusion solution in the refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours and at room temperature (20°C to 25°C [68°F to 77°F]) for up to 7 hours, including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature prior to administration.

20 PATIENT COUNSELING INFORMATION

Patients treated with bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal
items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to
CDC guidelines. Also see Fact Sheet for Patients, Parents and Caregivers.

21 CONTACT INFORMATION
For additional information visit:
www.bamlanivimab.com

If you have questions, please contact:
1-855-LillyC19 (1-855-545-5921)

Literature revised March 18, 2021

Eli Lilly and Company, Indianapolis, IN 46285, USA
Copyright © 2020, 2021, Eli Lilly and Company. All rights reserved.

B3.01-BAM-0006-EUA HCP-20210318